Generated by AI
Structure Therapeutics Inc. American Depositary Shares represent ownership interests in Structure Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small-molecule therapies for chronic metabolic and cardiopulmonary diseases with significant unmet medical needs. The company’s current programs center on medicines designed to target G protein-coupled receptors, a broad and important class of biological pathways involved in disease signaling. Its research pipeline includes candidates aimed at obesity and related metabolic conditions, as well as additional therapeutic areas within chronic disease management. Structure Therapeutics operates as a science-driven drug developer, combining discovery, preclinical work, and clinical-stage development to advance treatments intended for long-term use in specialized medical markets. The American Depositary Shares provide a U.S.-traded equity form for the company’s ordinary shares, giving market participants access to a biopharmaceutical business built around oral therapeutics and targeted receptor biology.
Website601 Gateway Boulevard
South San Francisco, CA, 94080
United States
The latest articles about GPCR.
Structure Therapeutics (GPCR) put its third quarter in focus for investors after reporting a wider net loss of US$144.76 million and a higher loss per share, with year-to-date figures showing a similar pattern. Structure Therapeutics’ share price has fallen sharply over 2026, with a year to date share price return of down 70.64% and a 90 day share price return of down 62.64%. The 1 year total shareholder return is down 46.58%, pointing to fading momentum as investors react to widening losses...
Summary of Oct 20's posts. Generated by AI.
Summary of Jan 20's posts. Generated by AI.
Summary of May 17's posts. Generated by AI.
Investors talking about GPCR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.